本帖最后由 老马 于 2012-1-13 21:20 编辑
1 u: {+ ?4 I, p8 b- b8 U
. @: U" T! O7 X2 M, v% D& }爱必妥和阿瓦斯丁的比较" E7 ]7 r; o' u
/ f _5 }- v3 }& f5 Z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/8 c# T. Q# f0 g1 E
! s z2 Q4 B1 P
; v& F9 s! A* zhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ s4 i( i5 }$ D# ?' m( D# e8 t==================================================& [) H% l0 ?1 o: M0 M
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); m. u, `5 _' |1 s- G1 r, [; T% W
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ s0 j/ P9 [5 ~5 u$ u& g5 ~5 {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& f& @6 b; Z6 ?9 i! R6 L
|